Features | VJHemOnc

ASH press briefing rundown: optimizing pediatric care

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

ASH press briefing rundown: new drugs and targets

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

ASH press briefing rundown: changing the status quo for blood cancers

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

VJSocial Media Masterclass – Social Media Strategy

Learn how to build a social media strategy effectively and appropriately alongside your clinical practice. Independent medical support by Janssen…

Biological therapy in NHL: treating with CAR-T versus BiTEs

VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…

VJSocial Media Masterclass – Engagement on Twitter

Learn how to engage on Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Highlights from the 2022 Third Annual Texas MPN Workshop (TMW)

VJHemOnc is excited to bring you the latest updates from the 2022 third annual Texas MPN Workshop, which brought together…

Teclistamab receives EMA approval for adult patients with relapsed/refractory (R/R) multiple myeloma

On August 24 2022, the European Medicines Agency (EMA) approved the use of teclistamab for the treatment of patients with…